356 related articles for article (PubMed ID: 31066365)
1. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions.
Kirchmayer U; Narduzzi S; Mayer F; Tuccori M; Leoni O; Belleudi V; Di Martino M; Lallo A; Addis A; Davoli M
Recenti Prog Med; 2019 Apr; 110(4):195-202. PubMed ID: 31066365
[TBL] [Abstract][Full Text] [Related]
2. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
Loo SY; Coulombe J; Dell'Aniello S; Brophy JM; Suissa S; Renoux C
BMJ Open; 2018 Jan; 8(1):e019638. PubMed ID: 29371284
[TBL] [Abstract][Full Text] [Related]
6. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.
Ferroni E; Gennaro N; Costa G; Fedeli U; Denas G; Pengo V; Corti MC
Int J Cardiol; 2019 Aug; 288():72-75. PubMed ID: 31043323
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.
Degli Esposti L; Andretta M; Di Pasquale G; Gambera M; Saragoni S; Perrone V; Buda S
Vasc Health Risk Manag; 2019; 15():429-437. PubMed ID: 31632047
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
Coleman CI; Peacock WF; Antz M
Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
[TBL] [Abstract][Full Text] [Related]
9. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
10. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.
Huiart L; Ferdynus C; Renoux C; Beaugrand A; Lafarge S; Bruneau L; Suissa S; Maillard O; Ranouil X
BMJ Open; 2018 Mar; 8(3):e018180. PubMed ID: 29602837
[TBL] [Abstract][Full Text] [Related]
11. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
12. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
14. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
Ashley J; McArthur E; Bota S; Harel Z; Battistella M; Molnar AO; Jun M; Badve SV; Garg AX; Manuel D; Tanuseputro P; Wells P; Mavrakanas T; Rhodes E; Sood MM
Am J Kidney Dis; 2020 Sep; 76(3):311-320. PubMed ID: 32333946
[TBL] [Abstract][Full Text] [Related]
15. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation.
Cataldo N; Pegoraro V; Ripellino C; Bertasi V; Di Turi R; Pastorello M; Gambera M
Recenti Prog Med; 2018 Feb; 109(2):113-121. PubMed ID: 29493635
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.
Denas G; Gennaro N; Ferroni E; Fedeli U; Saugo M; Zoppellaro G; Padayattil Jose S; Costa G; Corti MC; Andretta M; Pengo V
Int J Cardiol; 2017 Dec; 249():198-203. PubMed ID: 28935464
[TBL] [Abstract][Full Text] [Related]
17. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation.
Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L
JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038
[TBL] [Abstract][Full Text] [Related]
18. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
[TBL] [Abstract][Full Text] [Related]
19. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
Yu AYX; Malo S; Svenson LW; Wilton SB; Hill MD
J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29080863
[TBL] [Abstract][Full Text] [Related]
20. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
